Article
Medicine, General & Internal
R. L. Atmar, K. E. Lyke, M. E. Deming, L. A. Jackson, A. R. Branche, H. M. El Sahly, C. A. Rostad, J. M. Martin, C. Johnston, R. E. Rupp, M. J. Mulligan, R. C. Brady, R. W. Frenck, M. Backer, A. C. Kottkamp, T. M. Babu, K. Rajakumar, S. Edupuganti, D. Dobrzynski, R. N. Coler, C. M. Posavad, J. Archer, S. Crandon, S. U. Nayak, D. Szydlo, J. A. Zemanek, C. P. Dominguez Islas, E. R. Brown, M. S. Suthar, M. J. McElrath, A. B. McDermott, D. C. Montefiori, A. Eaton, K. M. Neuzil, D. S. Stephens, P. C. Roberts, J. H. Beigel
Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Arianna Pani, Alessandra Romandini, Alice Schianchi, Michele Senatore, Oscar M. Gagliardi, Gianluca Gazzaniga, Stefano Agliardi, Tommaso Conti, Paolo A. Schenardi, Matteo Maggi, Stefano D'Onghia, Valentina Panetta, Silvia Renica, Silvia Nerini Molteni, Chiara Vismara, Daniela Campisi, Michaela Bertuzzi, Simona Giroldi, Laura Zoppini, Mauro Moreno, Marco Merli, Marco Bosio, Massimo Puoti, Francesco Scaglione
Summary: This study evaluated the increase in antibody titers 14 days after the booster dose of BNT162b2. The results showed a potent universal antibody response regardless of pre-booster vaccine seronegativity.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Melanie Stecher, Anja Brathen Kristoffersen, Kristian Lie, Svein Rune Andersen, Hinta Meijerink, Jostein Starrfelt
Summary: Evidence from a cohort study in Norway indicates that a fourth dose of mRNA vaccine provides increased protection against severe outcomes of COVID-19, particularly among individuals aged 75 years and older. Bivalent vaccines show better protection compared to monovalent vaccines, but the protective effect diminishes over time.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
(2023)
Article
Medicine, General & Internal
Lorenzo Azzi, Daniela Dalla Gasperina, Giovanni Veronesi, Mariam Shallak, Vittorio Maurino, Andreina Baj, Francesco Gianfagna, Pierpaolo Cavallo, Francesco Dentali, Lucia Tettamanti, Fabrizio Maggi, Lorenzo Stefano Maffioli, Angelo Tagliabue, Roberto Sergio Accolla, Greta Forlani
Summary: Limited studies have been conducted on the development of mucosal immune response after BNT162b2-booster vaccination. Serum and saliva samples were collected from 50 healthcare workers before and after the booster dose. The results showed that the booster dose elicited a stronger systemic immune response but failed to activate effective mucosal immunity against the Omicron BA.1 variant.
Article
Immunology
Piotr Rzymski, Barbara Poniedzialek, Andrzej Fal
Summary: The study found that the majority of surveyed Poles are willing to receive a booster dose of the COVID-19 vaccine, with main concerns being the side effects from previous vaccinations, the opinion that further vaccinations are unnecessary, and existing safety uncertainties. Factors such as older age, obesity, chronic diseases, history of influenza vaccination, and pre/post-vaccination SARS-CoV-2 infections were more likely to influence individuals' attitudes towards receiving a booster dose.
Article
Immunology
Kavita Batra, Manoj Sharma, Chia-Liang Dai, Jagdish Khubchandani
Summary: This study investigated hesitancy, confidence, literacy, and the role of the multi-theory model (MTM) constructs in COVID-19 booster uptake. The findings revealed that among the booster hesitant group, a significantly larger proportion of respondents were unvaccinated with the primary series, younger in age, single or never married, had lower education, and identified themselves as Republicans. This hesitant group had lower mean scores of vaccine literacy and confidence, and had lower odds of behavioral confidence. Effective multi-theory-model-based communication campaigns are needed to raise public awareness.
Article
Immunology
Pavinee Assavavongwaikit, Napaporn Chantasrisawad, Orawan Himananto, Chayapa Phasomsap, Pintusorn Klawaja, Sapphire Cartledge, Rachaneekorn Nadsasarn, Thidarat Jupimai, Surinda Kawichai, Suvaporn Anugulruengkitt, Thanyawee Puthanakit
Summary: This study aims to compare the immunogenicity against Omicron before and after booster dose of BNT162b2 in healthy adolescents, and evaluate their attitudes towards booster dose vaccination. The results show that a booster dose of BNT162b2 elicits high immunogenicity against the Omicron variant, and the main motivation for receiving booster doses is to reduce the risk of infection.
Review
Immunology
Vivek P. Chavda, Disha R. Vihol, Hetvi K. Solanki, Vasso Apostolopoulos
Summary: The outbreak of SARS-CoV-2 has posed a severe threat to global health, but the development and distribution of vaccines have brought hope. Currently, there are more than 47 vaccines approved for emergency use worldwide, with India playing a significant role in vaccine production.
Article
Oncology
Carolin Krekeler, Lea Reitnauer, Ulrike Bacher, Cyrus Khandanpour, Leander Steger, Goran Ramin Boeckel, Justine Klosner, Phil-Robin Tepasse, Marcel Kemper, Marc Tim Hennies, Rolf Mesters, Matthias Stelljes, Norbert Schmitz, Andrea Kerkhoff, Christoph Schliemann, Jan-Henrik Mikesch, Nicole Schmidt, Georg Lenz, Annalen Bleckmann, Evgenii Shumilov
Summary: This study provides data on the efficacy of COVID-19 prime-boost vaccines in patients with hematologic malignancies and offers guidance for managing weak or failed responses to the vaccines. The study found that 55% of the patients achieved seroconversion after vaccination. Factors such as age, lymphocytopenia, ongoing treatment, and anti-CD20 B-cell depletion were predictors of booster failure. Passive immunization was associated with a lower risk of breakthrough infections.
Article
Immunology
Ariel Israel, Eugene Merzon, Yotam Shenhar, Ilan Green, Avivit Golan-Cohen, Alejandro A. Schaffer, Eytan Ruppin, Shlomo Vinker, Eli Magen
Summary: A population-based study in Israel found that individuals with chronic kidney disease and anemia had higher rates of COVID-19 infection within 14 days after booster vaccination.
Article
Immunology
Chung-Jong Kim, Ji-Yun Bae, Kang-Il Jun, Jihee Kim, Hee-Jung Son, Hae-Sun Chung, Soo-Kyung Kim, Soohyun Kim, Dohsik Minn, Hee-Jung Choi
Summary: This study investigates the efficacy of different COVID-19 booster vaccines and finds that booster vaccination after two prior vaccinations significantly increases serum antibody levels, regardless of the type of vaccine administered.
Article
Immunology
Kirsten Barnes, Ben Colagiuri
Summary: This study investigated the factors predicting the intention to receive a COVID-19 booster vaccine and found key predictors related to psychological perceptions of the vaccine and the virus. These findings are crucial for maintaining participation in the COVID-19 vaccination program and provide a theoretical basis for future behavioral research in this area.
Article
Multidisciplinary Sciences
Daryl Geers, Roos S. G. Sablerolles, Debbie van Baarle, Neeltje A. Kootstra, Wim J. R. Rietdijk, Katharina S. Schmitz, Lennert Gommers, Susanne Bogers, Nella J. Nieuwkoop, Laura L. A. van Dijk, Eva van Haren, Melvin Lafeber, Virgil A. S. H. Dalm, Abraham Goorhuis, Douwe F. Postma, Leo G. Visser, Anke L. W. Huckriede, Alessandro Sette, Alba Grifoni, Rik L. de Swart, Marion P. G. Koopmans, P. Hugo M. van der Kuy, Corine H. GeurtsvanKessel, Rory D. de Vries
Summary: The study found that booster vaccinations after Ad26.COV2.S priming, especially heterologous boosters, could significantly increase functional antibodies targeting both ancestral and emerging variants of SARS-CoV-2. Meanwhile, T-cell responses remained similar and cross-reactive towards the variants regardless of homologous or heterologous booster vaccination. Additionally, minimal expansion of SARS-CoV-2-specific T-cell clones and no increase in the breadth of the T-cell repertoire were observed after booster vaccination. These findings suggest that Ad26.COV2.S priming provides a solid immunological foundation for heterologous boosting, enhancing humoral and cellular immune responses against emerging variants of concern.
Article
Multidisciplinary Sciences
Daniel Mrak, Daniela Sieghart, Elisabeth Simader, Selma Tobudic, Helga Radner, Peter Mandl, Lisa Goeschl, Maximilian Koblischke, Nikolaus Hommer, Angelika Wagner, Margareta Mayer, Lorenz Schubert, Lukas Hartl, Karin Kozbial, Philipp Hofer, Felix Kartnig, Thomas Hummel, Andreas Kerschbaumer, Thomas Deimel, Antonia Puchner, Venugopal Gudipati, Renate Thalhammer, Petra Munda, Keziban Uyanik-Uenal, Andreas Zuckermann, Gottfried Novacek, Thomas Reiberger, Erika Garner-Spitzer, Roman Reindl-Schwaighofer, Renate Kain, Stefan Winkler, Josef S. Smolen, Karin Stiasny, Gottfried F. Fischer, Thomas Perkmann, Helmuth Haslacher, Markus Zeitlinger, Ursula Wiedermann, Judith H. Aberle, Daniel Aletaha, Leonhard X. Heinz, Michael Bonelli
Summary: Optimizing COVID-19 vaccination strategies for immunosuppressed patients is crucial. In this clinical trial, a homologous mRNA booster vaccine showed higher seroconversion rate compared to a switch to a vector-based vaccine for non-seroconverted immunosuppressed patients. The study highlights the importance of booster vaccination and supports the use of homologous mRNA booster vaccine in this vulnerable group.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Geetanjali C. Achrekar, Kavita Batra, Yashashri Urankar, Ravi Batra, Naved Iqbal, Sabiha A. Choudhury, Deepti Hooda, Roohi Khan, Suraj Arora, Aditi Singh, Francesco Chirico, Manoj Sharma
Summary: This study aimed to investigate the acceptance of booster doses of the COVID-19 vaccine and its associated predictors among the Indian population. Over 50% of the participants expressed their willingness to receive booster doses. Among those who were not willing to take the booster dose, a higher proportion of them were unvaccinated with the primary series, had a lower income, lived in rural areas, did not live with vulnerable individuals, and did not have family or friends who had tested positive for COVID-19.